Abbott Labs Increases Price Target Following Strong Q3 Results
In a recent update, BTIG has increased its price target for Abbott Laboratories (NYSE: ABT) from $135 to $139 while maintaining a Buy rating on the stock. This revision comes after a strong performance from the company in the third quarter, surpassing revenue expectations by $91 million primarily due to significant growth in its Medical Devices segment.
Significant Revenue Growth Highlights Abbott's Performance
Abbott's reported revenue for the quarter reached $10.635 billion, which translates into an impressive organic growth rate of 8.2% year-over-year when COVID-19 test sales are excluded. With this growth trajectory, Abbott not only surpassed consensus estimates of $10.544 billion but also demonstrated a solid performance across various business sectors.
Medical Devices Sector Achieves Notable Milestones
The Medical Devices segment was a standout performer, showcasing a remarkable 13.3% year-over-year organic growth that exceeded initial estimates by $81 million. Although sales from COVID-19 tests were not factored into expectations, they nevertheless contributed significantly to a higher performance in the Diagnostics segment, with a $146 million increase above consensus when included.
Abbott's Positive Outlook and Future Guidance
Abbott's earnings per share (EPS) were also encouraging, with adjusted EPS of $1.21 beating forecasts by a penny. Gross margins met expectations while operating expenses were slightly above the consensus. Looking ahead, Abbott has updated its full-year guidance, projecting an adjusted EPS range of $4.64 to $4.70 and a GAAP EPS forecast of $3.34 to $3.40. For the fourth quarter, the company anticipates adjusted EPS between $1.31 and $1.37, closely aligning with the consensus estimate of $1.34.
Device Segment’s Competitive Edge
In terms of industry performance, Abbott's growth in its Devices sector has outmatched many of its peers in the MedTech industry. Notably, six out of seven Device business units recorded results above expectations. Key drivers of this growth include advancements in the Electrophysiology division, the launch of Lingo OTC CGM, and increased market share in Structural Heart products.
Management Confidence and Strategic Initiatives
Abbott's management has expressed strong confidence in achieving high single-digit revenue growth alongside nearly 10% EPS growth by 2025, which BTIG perceives as a solid foundation for future performance. The company is also committed to resolving ongoing infant formula litigation efficiently, indicating a proactive approach.
Analysts Maintain Optimistic View
Looking ahead to 2024, BTIG projects a year-over-year organic sales growth of about 9.7% for Abbott, excluding COVID test sales. Analysts anticipate further sales and adjusted EPS outperformance in the fourth quarter and beyond, driven by sustainable growth in top Device franchises, new product launches, improved margins, and a newly announced $7 billion share repurchase authorization.
Consistent Performance in Financial Metrics
Abbott has established a commendable track record of maintaining dividend payments for 54 consecutive years, with 11 of those years reflecting positive growth in dividends. Currently, the company boasts a dividend yield of 1.9%, emphasizing its dedication to returning value to shareholders. Over the past year, Abbott has yielded a total return of 28.41%, further affirming the positive trends indicated in its financial results.
A Leader in the Healthcare Industry
As a significant player in the Healthcare Equipment & Supplies industry, Abbott excels in its Medical Devices performance. The company's capacity to generate cash flows that comfortably cover interest payments speaks to its robust financial standing, enabling ongoing growth and market expansion efforts.
Frequently Asked Questions
What is the new price target for Abbott Laboratories?
BTIG has raised the price target for Abbott Laboratories to $139 from $135.
What was Abbott’s reported revenue for the third quarter?
Abbott reported a total revenue of $10.635 billion for the third quarter, surpassing expectations.
How did Abbott's Medical Devices segment perform?
The Medical Devices segment achieved a notable 13.3% year-over-year organic growth, exceeding estimates.
What is Abbott's projected EPS range for the full year?
Abbott expects an adjusted EPS range of $4.64 to $4.70 for the full year.
How long has Abbott been paying dividends?
Abbott has maintained dividends for 54 consecutive years, with a consistent growth rate over the last 11 years.
